Cancer screening (USPSTF)
Also known as: screening guidelines · USPSTF grades
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
USPSTF A and B Recommendations (cancer screening recommendations)
U.S. Preventive Services Task Force (USPSTF) · 2026 · Rolling list of current final A/B recommendations, accessed July 2026
The USPSTF issues topic-by-topic cancer screening recommendations rather than a single combined document, and revises each on its own cycle. This official list of graded A and B recommendations is the authoritative index of which cancer screenings the Task Force currently endorses and links to each individual statement.
- Grades A and B mark services the Task Force judges to have high or moderate net benefit. source
- Current cancer screening entries include breast cancer (2024), colorectal cancer (2021), lung cancer (2021) and cervical cancer (2018). source
- The USPSTF describes itself as a scientifically independent panel of primary care and prevention experts that systematically reviews the evidence. source
Council Recommendation of 9 December 2022 on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC
Council of the European Union · 2022 · 2022/C 473/01
The EU-level reference point for organised cancer screening, adopted by the Council in December 2022 under Europe's Beating Cancer Plan. It replaces the 2003 recommendation and widens the scope beyond breast, cervical and colorectal cancer. Member states remain responsible for running their own national programmes.
- Adopted by the Council of the EU on 9 December 2022, replacing Council Recommendation 2003/878/EC. source
- Extends the target list beyond breast, cervical and colorectal cancer to include lung, prostate and, in high-incidence settings, gastric cancer. source
- Sets an aim that 90% of the eligible EU population be offered breast, cervical and colorectal screening by 2025. source
US vs EU key differences
- Breast screening starts earlier in the US: the USPSTF gives a B grade to biennial mammography from age 40 to 74, while the EU Council Recommendation sets the target population at 45 to 74, itself an extension of the older 50-69 range. source
- Colorectal screening ages differ: the US covers 45 to 75 (A grade for 50-75, B grade for 45-49) with a menu of test options, whereas the EU recommendation targets 50 to 74 and names faecal immunochemical testing as the primary test. source
- Cervical screening structure differs: the USPSTF still supports cytology every three years from age 21 and several strategies for ages 30-65, while the EU recommendation is built around HPV testing in women aged 30 to 65 at intervals of five years or more. source
- Lung screening is a firm clinical recommendation in the US (annual low-dose CT for adults 50-80 with a 20 pack-year history) but is framed in the EU only as feasibility to be explored by member states in heavy current and former smokers aged 50 to 75. source
- The EU document reaches cancers the USPSTF does not endorse at A or B level, asking member states to assess organised prostate screening in men up to 70 and, where gastric cancer burden is high, strategies based on Helicobacter pylori testing. source
- The instruments are different in kind: USPSTF issues graded recommendations aimed at individual clinicians and tied to US insurance coverage rules, whereas the 2022 Council Recommendation is a non-binding policy instrument directing member states to organise population screening programmes. source
What changed recently
- EU2003/878/EC → 2022/C 473/012022-12-09
The 2022 Council Recommendation widened the EU screening framework beyond the breast, cervical and colorectal cancers covered in 2003, adding lung, prostate and gastric cancer for feasibility assessment. It also extended the breast screening age band to roughly 45-74 and made HPV testing the preferred cervical screening method for women aged 30-65.
source ↗curation confidence 90%
See the full update feed for changes across every system.